Transcriptomics

Dataset Information

0

Treatment of MCF-7 cells with TRAIL and Smac mimetic (LCL-161) [array]

ABSTRACT: The aim was to identify changes in gene expression in MCF-7 cells induced by a combination of TRAIL and LCL-161. Treated samples and control samples were collected after 24 h of treatment and after 96 h of treatment followed by a three-day period in normal medium.

ORGANISM(S): Homo sapiens

PROVIDER: GSE122307 | GEO | 2022/06/30

REPOSITORIES: GEO

Json Xml

Similar Datasets

Transcriptomics Treatment of MCF-7 cells with TRAIL and Smac mimetic (LCL-161) [seq]
2021-02-24 | GSE122979 | GEO
Genomics Treatment of MCF-7 cells with TRAIL and Smac mimetic (LCL-161)
| PRJNA507104 | ENA
Genomics Treatment of MCF-7 cells with TRAIL and Smac mimetic (LCL-161) [seq]
| PRJNA507110 | ENA
Genomics Treatment of MCF-7 cells with TRAIL and Smac mimetic (LCL-161) [array]
| PRJNA504559 | ENA
Transcriptomics Treatment of MCF-7 cells with TRAIL and Smac mimetic (LCL-161)
2021-02-24 | GSE122980 | GEO
Unknown The SMAC mimetic LCL-161 selectively targets JAK2V617F mutant cells.
| S-EPMC6941266 | biostudies-literature
Unknown The SMAC mimetic LCL-161 displays antitumor activity in preclinical models of rituximab-resistant B-cell lymphoma.
| S-EPMC6290104 | biostudies-literature
Unknown The SMAC mimetic, LCL-161, reduces survival in aggressive MYC-driven lymphoma while promoting susceptibility to endotoxic shock.
| S-EPMC4848837 | biostudies-other
Unknown Smac mimetic reverses resistance to TRAIL and chemotherapy in human urothelial cancer cells.
| S-EPMC3230293 | biostudies-literature
Genomics LCL Capture-C
| PRJNA795785 | ENA